Hims & Hers Health’s Peptide Opportunity Tempered By FDA Recommendation, Says Analyst

Article summary

HIMS facing negative impact on peptide optionality due to FDA's recommendation against adding 7 peptides to bulk list. BofA raises PT to $36.